I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.
June 22, 2017
On an upside, wing and more than a prayer
The IBB foretells a +0.29% and stays as strong
I’d say, look up “black swans”
Pre-open indication: seven (7), 3 BUY and 4 SELLS
A critical indication ahead of “our” universe’s open!
Are you a subscriber? If not – you’re missing the realities of “our” universe!
June 1, 2017
Calling out the recent 10-Q page 17’s paragraph re a 24 page legal filing - this is what BSTG did NOT want investors to know or read!
May 31, 2017
CYTX jumps +$0.04 or +4.08% to $1.01 with 113.05 shares traded – it’s still ONLY an OPTION - something is better than ... nothing!
January 28, 2017
What difference does a $1.00 subscription a day, $100.00 a quarter abating the lack of a portfolio ... enema!
Subscribe: http://www.regmedinvestors.com/create-account
June 21, 2017
Indexes also sing the tune, IBB up +4.12%, XBI up +4.71% as the XLV trails at +1.27%
As I had stated, my concern was the IBB and its ability to stay UP beyond the pre-market indication +0.1% … it did!
Time element of growth is momentum based
Pricing expectations are still in jeopardy as to the context of a sustainable breakout
Pre-open indications re-cap: 3 hit and 2 miss;
Out and about: ImmunoCellular Therapeutics (NYSEMKT: IMUC) Suspends further patient randomization for ICT-107 P3 Trial
I answer one question, in which company should investors commit and keep their money.
What have you missed, Wednesday’s results have implications to Thursday's sector activity.
June 20, 2017
SGMO closes UP +$0.25 to $8.20 and promptly dives -$0.70 or -8.54% to $7.50 SGMO prices 10 M shares at $7.25
June 13, 2017
AST is UP +$0.25 or +7.94% in the pre-market
June 12, 2017
FCSC is up +$0.23 or +9.27% in the pre-market, it's a BUY with an exit defined in short timing ... news has a life cycle in this market
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2017 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
